Literature DB >> 27287891

Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.

Rui Xue Zhang1, Ho Lun Wong2, Hui Yi Xue2, June Young Eoh2, Xiao Yu Wu1.   

Abstract

Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Nanomedicine; Perspectives; Strategies; Synergistic drug combinations

Mesh:

Substances:

Year:  2016        PMID: 27287891      PMCID: PMC5064882          DOI: 10.1016/j.jconrel.2016.06.012

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  139 in total

1.  Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.

Authors:  Elvin Blanco; Takafumi Sangai; Suhong Wu; Angela Hsiao; Guillermo U Ruiz-Esparza; Carlos A Gonzalez-Delgado; Francisca E Cara; Sergio Granados-Principal; Kurt W Evans; Argun Akcakanat; Ying Wang; Kim-Anh Do; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Ther       Date:  2014-02-26       Impact factor: 11.454

2.  Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.

Authors:  Ho Lun Wong; Zancong Shen; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  Mol Pharm       Date:  2011-03-29       Impact factor: 4.939

3.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew Mike Rauth; Xiao Yu Wu
Journal:  J Control Release       Date:  2006-09-26       Impact factor: 9.776

4.  Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.

Authors:  Chunbai He; Demin Liu; Wenbin Lin
Journal:  Biomaterials       Date:  2014-10-12       Impact factor: 12.479

5.  Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.

Authors:  Guo Zhang; Margaret A Park; Clint Mitchell; Hossein Hamed; Mohamed Rahmani; Aditi Pandya Martin; David T Curiel; Adly Yacoub; Martin Graf; Ray Lee; John D Roberts; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

6.  Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew Mike Rauth; Xiao Yu Wu
Journal:  J Pharm Sci       Date:  2004-08       Impact factor: 3.534

7.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

8.  Combination drug delivery approaches in metastatic breast cancer.

Authors:  Jun H Lee; Anjan Nan
Journal:  J Drug Deliv       Date:  2012-04-26

9.  Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds.

Authors:  Chih-Sheng Chiang; Shang-Hsiu Hu; Bang-Jie Liao; Yuan-Ching Chang; San-Yuan Chen
Journal:  Nanomedicine       Date:  2013-07-24       Impact factor: 5.307

Review 10.  Single agent versus combination chemotherapy for metastatic breast cancer.

Authors:  Sue Carrick; Sharon Parker; Charlene E Thornton; Davina Ghersi; John Simes; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
View more
  38 in total

Review 1.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 2.  Potential applications of nanoparticles in cancer immunotherapy.

Authors:  Yimei Jia; Abdelwahab Omri; Lakshmi Krishnan; Michael J McCluskie
Journal:  Hum Vaccin Immunother       Date:  2016-11-21       Impact factor: 3.452

Review 3.  A Decade of Organs-on-a-Chip Emulating Human Physiology at the Microscale: A Critical Status Report on Progress in Toxicology and Pharmacology.

Authors:  Mario Rothbauer; Barbara E M Bachmann; Christoph Eilenberger; Sebastian R A Kratz; Sarah Spitz; Gregor Höll; Peter Ertl
Journal:  Micromachines (Basel)       Date:  2021-04-21       Impact factor: 2.891

Review 4.  Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer.

Authors:  Fan Lei; Xinyuan Xi; Surinder K Batra; Tatiana K Bronich
Journal:  J Pharmacol Exp Ther       Date:  2019-02-22       Impact factor: 4.030

Review 5.  Nanoparticle-hydrogel superstructures for biomedical applications.

Authors:  Yao Jiang; Nishta Krishnan; Jiyoung Heo; Ronnie H Fang; Liangfang Zhang
Journal:  J Control Release       Date:  2020-05-26       Impact factor: 9.776

6.  Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.

Authors:  Rui Xue Zhang; Tian Zhang; King Chen; Ji Cheng; Paris Lai; Andrew M Rauth; K Sandy Pang; Xiao Yu Wu
Journal:  J Vis Exp       Date:  2017-10-05       Impact factor: 1.355

Review 7.  Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.

Authors:  Rui Xue Zhang; Jason Li; Tian Zhang; Mohammad A Amini; Chunsheng He; Brian Lu; Taksim Ahmed; HoYin Lip; Andrew M Rauth; Xiao Yu Wu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

8.  Norcantharidin combined with 2-deoxy-d-glucose suppresses the hepatocellular carcinoma cells proliferation and migration.

Authors:  Ragini Singh; Shuang Cheng; Jun Li; Santosh Kumar; Qinghua Zeng; Qingmei Zeng
Journal:  3 Biotech       Date:  2021-02-25       Impact factor: 2.406

9.  Co-delivery of 5-Fluorouracil and Curcumin Nanohybrid Formulations for Improved Chemotherapy Against Oral Squamous Cell Carcinoma.

Authors:  Saurabh Srivastava; Shadab Mohammad; Aditya Bhushan Pant; Prabhat Ranjan Mishra; Gitu Pandey; Shalini Gupta; Sana Farooqui
Journal:  J Maxillofac Oral Surg       Date:  2018-06-01

10.  Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles.

Authors:  Hee Ji Shin; Min Jeong Jo; Ik Sup Jin; Chun-Woong Park; Jin-Seok Kim; Dae Hwan Shin
Journal:  Int J Nanomedicine       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.